IS8521A - Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi - Google Patents
Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á AlzheimerssjúkdómiInfo
- Publication number
- IS8521A IS8521A IS8521A IS8521A IS8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A IS 8521 A IS8521 A IS 8521A
- Authority
- IS
- Iceland
- Prior art keywords
- disease
- treatment
- alzheimer
- beta
- tricyclic indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0328900.6A GB0328900D0 (en) | 2003-12-12 | 2003-12-12 | Novel compounds |
| PCT/EP2004/014076 WO2005058915A1 (en) | 2003-12-12 | 2004-12-09 | Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8521A true IS8521A (is) | 2006-06-26 |
Family
ID=30130158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8521A IS8521A (is) | 2003-12-12 | 2006-06-26 | Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070073060A1 (no) |
| EP (1) | EP1692143B1 (no) |
| JP (1) | JP2007513913A (no) |
| KR (1) | KR20060121164A (no) |
| CN (1) | CN1914214A (no) |
| AT (1) | ATE414090T1 (no) |
| AU (1) | AU2004299231A1 (no) |
| BR (1) | BRPI0417476A (no) |
| CA (1) | CA2549072A1 (no) |
| DE (1) | DE602004017777D1 (no) |
| GB (1) | GB0328900D0 (no) |
| IL (1) | IL175819A0 (no) |
| IS (1) | IS8521A (no) |
| MA (1) | MA28241A1 (no) |
| NO (1) | NO20063137L (no) |
| RU (1) | RU2006124863A (no) |
| WO (1) | WO2005058915A1 (no) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087751A2 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| WO2006010095A2 (en) | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| MX2007003281A (es) * | 2004-09-21 | 2007-05-18 | Pfizer Prod Inc | N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central. |
| GB0422766D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| GB0422765D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| WO2007047305A1 (en) * | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| FR2919289B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| FR2919285B1 (fr) | 2007-07-27 | 2012-08-31 | Sanofi Aventis | Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique. |
| FR2919288B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique. |
| BRPI0813094A2 (pt) * | 2007-07-27 | 2014-12-23 | Sanofi Aventis | Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica. |
| MX2010012807A (es) * | 2008-05-29 | 2010-12-21 | Albany Molecular Res Inc | Moduladores del rceptor 5-hidroxitriptamina 3, metodos de fabricacion y uso de los mismos. |
| FR2960876B1 (fr) | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| CA2801074A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| MX365851B (es) * | 2012-08-24 | 2019-06-17 | Treventis Corp | Compuestos de benzofurazano anti-amiloides y metodos. |
| WO2019075358A1 (en) * | 2017-10-13 | 2019-04-18 | Ghosh Arun K | BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| US12043631B2 (en) | 2017-10-13 | 2024-07-23 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU749281B2 (en) * | 1997-02-04 | 2002-06-20 | Regents Of The University Of California, The | Nanomolar, non-peptide inhibitors of cathepsin D |
| US6207664B1 (en) * | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
| CA2401749A1 (en) * | 2000-03-23 | 2001-09-27 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| MXPA02012560A (es) * | 2000-06-30 | 2003-05-14 | Elan Pharm Inc | Compuestos para tratar la enfermedad de alzheimer. |
| RS50504A (en) * | 2001-11-08 | 2007-04-10 | Elan Pharmaceuticals Inc., | N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives |
| GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-12-12 GB GBGB0328900.6A patent/GB0328900D0/en not_active Ceased
-
2004
- 2004-12-09 US US10/596,296 patent/US20070073060A1/en not_active Abandoned
- 2004-12-09 JP JP2006543488A patent/JP2007513913A/ja not_active Withdrawn
- 2004-12-09 KR KR1020067011376A patent/KR20060121164A/ko not_active Application Discontinuation
- 2004-12-09 WO PCT/EP2004/014076 patent/WO2005058915A1/en active Application Filing
- 2004-12-09 RU RU2006124863/04A patent/RU2006124863A/ru not_active Application Discontinuation
- 2004-12-09 BR BRPI0417476-3A patent/BRPI0417476A/pt not_active IP Right Cessation
- 2004-12-09 AT AT04803724T patent/ATE414090T1/de not_active IP Right Cessation
- 2004-12-09 CA CA002549072A patent/CA2549072A1/en not_active Abandoned
- 2004-12-09 EP EP04803724A patent/EP1692143B1/en active Active
- 2004-12-09 AU AU2004299231A patent/AU2004299231A1/en not_active Abandoned
- 2004-12-09 CN CNA2004800416435A patent/CN1914214A/zh active Pending
- 2004-12-09 DE DE602004017777T patent/DE602004017777D1/de not_active Expired - Fee Related
-
2006
- 2006-05-22 IL IL175819A patent/IL175819A0/en unknown
- 2006-06-26 MA MA29143A patent/MA28241A1/fr unknown
- 2006-06-26 IS IS8521A patent/IS8521A/xx unknown
- 2006-07-06 NO NO20063137A patent/NO20063137L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2549072A1 (en) | 2005-06-30 |
| CN1914214A (zh) | 2007-02-14 |
| BRPI0417476A (pt) | 2007-05-08 |
| US20070073060A1 (en) | 2007-03-29 |
| GB0328900D0 (en) | 2004-01-14 |
| MA28241A1 (fr) | 2006-10-02 |
| ATE414090T1 (de) | 2008-11-15 |
| EP1692143A1 (en) | 2006-08-23 |
| RU2006124863A (ru) | 2008-01-20 |
| IL175819A0 (en) | 2006-10-05 |
| JP2007513913A (ja) | 2007-05-31 |
| NO20063137L (no) | 2006-08-31 |
| EP1692143B1 (en) | 2008-11-12 |
| AU2004299231A1 (en) | 2005-06-30 |
| WO2005058915A1 (en) | 2005-06-30 |
| KR20060121164A (ko) | 2006-11-28 |
| DE602004017777D1 (de) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8521A (is) | Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi | |
| IS7925A (is) | Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm | |
| BRPI0409622A (pt) | derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer | |
| CY1111086T1 (el) | Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace) | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| WO2004080376A3 (en) | Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| WO2007019078A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| EP1912963A4 (en) | CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| IL165996A0 (en) | Novel thiophene acyl hydrazino derivatives method for preparing same use thereof as medicines pharmaceutical compositions and novel use |